ROSE-010 2026: Can a GLP-1 Be Inhaled?

ROSE-010 is an investigational, rapid-acting GLP-1 receptor agonist now being developed as a dry-powder inhaler. A September 2026 agreement pairs Rose Pharma’s peptide program with MannKind’s Technosphere delivery platform. The idea is real, but the inhaled product is still in development and has not yet shown weight-loss results in a completed human efficacy trial.

Most GLP-1 medicines are built to last. ROSE-010 is built around a different idea: act quickly, work around a meal and then clear more quickly.

That alone makes the program unusual. The new delivery plan makes it more so. Instead of another weekly injection or daily tablet, Rose Pharma and MannKind want to place a peptide GLP-1 into a small dry-powder inhaler.

The appeal is easy to understand. An inhaler could be needle-free, portable and fast. The hard part is everything hidden inside that simple gesture. The powder has to leave the device consistently, reach the right part of the lung, dissolve, cross into the body and produce a predictable effect without creating an unacceptable burden for the user.

ROSE-010 is therefore more than another obesity pipeline name. It is a useful test of whether inhaled delivery can give a peptide a distinct role in a market already crowded with injections, tablets and long-acting molecules.

What happened with ROSE-010 in September 2026?

MannKind and Rose Pharma announced a licensing and collaboration agreement on September 9, 2026. Under the agreement, Rose Pharma will use MannKind’s Technosphere dry-powder platform to develop an inhaled version of ROSE-010. MannKind will provide development and manufacturing support through Phase 1b.

This is important wording. The announcement does not say that an inhaled GLP-1 medicine is ready for sale. It says two companies have joined the molecule and delivery work needed to move an investigational product toward early clinical testing.

Rose Pharma brings the GLP-1 analogue and the clinical history of the underlying molecule. MannKind brings experience with a pulmonary powder platform, device integration and manufacturing. The agreement makes technical sense because an inhaled peptide is not only a peptide project. It is also a particle-engineering, device and lung-delivery project.

For the wider peptide industry, the news matters because it creates another route between a biological signal and the patient. Oral delivery gets most of the attention, but the lung can also provide a large, highly vascular surface for systemic absorption. That opportunity comes with a different set of controls and risks.

Is ROSE-010 already an inhaled drug?

ROSE-010 is the molecule. The inhaled dry-powder product is the current development program. Those two facts should not be collapsed into one.

The underlying compound has been studied before. Rose Pharma says four human trials have been completed with ROSE-010, including work in people with irritable bowel syndrome and a Phase 2a study that looked at appetite and food intake in adults with overweight or obesity. Those studies gave the company information about the molecule, but they did not establish that a Technosphere inhaler will deliver the same exposure or produce the same clinical result.

Changing the route changes the product. A subcutaneous dose passes through tissue under the skin. An inhaled dose must first behave like a well-controlled aerosol, deposit in the lung and dissolve. The resulting concentration curve may be faster, lower, higher or more variable depending on the formulation, inhalation technique and device.

That is why the most accurate answer in 2026 is straightforward: ROSE-010 has human research behind the molecule, while the new inhaled formulation still has to prove its own performance.

Why develop a short-acting GLP-1 when weekly drugs already exist?

Long action is valuable when the goal is steady receptor activity with infrequent dosing. It is not the only useful design.

Rose Pharma is exploring a meal-linked approach. The company describes ROSE-010 as fast acting and short lasting, with the intent to influence appetite around a defined eating event. In theory, that could give users more control over when the effect occurs and reduce continuous exposure between meals.

That does not mean a short-acting inhaler is proven to be better than a weekly injection. It means the product is being built for a different job. A hammer and a screwdriver can both be useful without being substitutes.

This distinction also matters commercially. The next phase of the GLP-1 market will not be won only by molecules that produce the largest number in a weight-loss trial. Convenience, tolerability, dose flexibility, manufacturing capacity and the place a product fits in a person’s routine can all shape demand.

An inhaled product may eventually appeal to people who dislike needles or want an option tied to particular meals. It may also face questions about inhalation technique, lung screening, device cost and real-world consistency. Early clinical studies have to show which side of that tradeoff carries more weight.

What did the earlier ROSE-010 appetite study find?

Rose Pharma has presented results from a randomized, placebo-controlled Phase 2a study of subcutaneous ROSE-010 in adults with overweight or obesity. According to the company’s scientific poster, participants who received the 150-microgram dose ate up to 17 percent less at a test meal than participants receiving placebo.

That is an interesting signal because it fits the intended rapid, meal-time profile. It is not the same as a weight-loss result. Eating less during one controlled meal does not tell us how body weight changes over months, whether the effect remains consistent or how an inhaled version will behave.

The route matters here. The study used a subcutaneous formulation. The new MannKind collaboration is about a dry powder delivered to the lung. It is reasonable to use the prior study as evidence that the molecule can affect a relevant human behavior. It is not reasonable to copy the percentage onto an inhaler page as if the final product had already produced it.

This careful distinction makes the commercial story stronger, not weaker. A buyer or partner can see exactly what has been demonstrated, what remains open and why the next development step exists.

How can an inhaled peptide reach the bloodstream?

The deep lung contains millions of tiny air sacs with thin walls and a rich blood supply. A properly designed particle can travel with the inhaled air, settle in that region, dissolve in the lung fluid and allow an active molecule to cross into the circulation.

The phrase “properly designed” is doing a great deal of work.

Particles that are too large may stop in the mouth or throat. Particles that are too small may be breathed back out. Moisture can make powder clump, which changes how it leaves the device. A user who inhales weakly may receive a different lung dose from a user who inhales with more force unless the product is designed and tested for that range.

MannKind’s Technosphere platform uses engineered dry-powder particles intended to carry an active ingredient into the lung. The company already uses the platform in an approved inhaled insulin product, which shows that the general delivery system can support a peptide. It does not automatically prove that ROSE-010 will have the required dose, stability, tolerability or clinical effect. Each active ingredient creates its own formulation problem.

Older preclinical pulmonary-delivery research has also shown that GLP-1 receptor agonist activity can be achieved through pulmonary delivery in animal models. That supports the route as biologically plausible. Human product development still has to answer the practical questions.

How does ROSE-010 compare with injectable and oral GLP-1 products?

The clearest comparison is not “which one wins?” It is “what problem is each format trying to solve?”

Approach	Basic design	Intended experience	Development reality in 2026
ROSE-010 inhaler	Short-acting peptide in a pulmonary dry powder	Fast, needle-free use around a meal	Investigational formulation and early clinical-development work
Long-acting injectable peptide	Modified peptide with extended exposure	Steady action with weekly or less frequent injections	Several mature and approved programs, depending on the molecule
Oral peptide GLP-1	Peptide plus an absorption strategy	Swallowed tablet without a needle	Proven possible, but absorption and instructions can be demanding
Oral small-molecule GLP-1	Non-peptide receptor agonist	Conventional pill-like format	Several late-stage programs, with molecule-specific safety and efficacy profiles

ROSE-010 should not be called an inhaled semaglutide. It is a different molecule with a different duration and development goal. Readers who want the basics of the established peptide can start with what semaglutide is. Our guide to oral peptide delivery in 2026 explains why a swallowed peptide faces a different barrier from an inhaled powder.

The comparison also shows why delivery is becoming a competitive category of its own. Two programs can activate the same receptor yet require completely different suppliers, tests, devices and manufacturing facilities.

What has to be manufactured besides the peptide?

An inhaled product is a system. The peptide API is only one part.

First, the molecule has to be produced with controlled identity, purity, content and impurity profile. Then it must be incorporated into a powder with the physical properties needed for the selected delivery platform. The formulation and filling process must preserve chemical stability while controlling how much powder enters each device or dose unit.

The device has to release that powder reproducibly. The package has to protect it from humidity and physical damage. The analytical program has to measure what comes out, not only what went in.

For a conventional peptide vial, buyers often focus on HPLC purity and mass-spectrometry identity. Those tests remain important, but they cannot answer whether an inhaler emits the correct dose or whether the particles reach a useful part of the respiratory tract.

An inhaled-development program may need tests for aerodynamic particle-size distribution, emitted dose, fine-particle dose, water content, powder flow, device resistance, extractables, leachables and performance through the intended shelf life. The exact panel depends on the product and development stage.

This is why a supplier conversation must begin with scope. “We need an inhaled peptide” is not enough. A project may need characterized raw API, a feasibility batch, formulation screening, device-compatible powder, filled clinical units or a complete regulated development package. Each request belongs to a different part of the supply chain.

Why particle engineering can be harder than it looks

A powder can appear fine to the eye and still be a poor aerosol.

Inhaled particles interact through electrostatic charge, surface texture and moisture. They can stick to one another, to a capsule or blister, and to the device itself. The force needed to break those contacts affects how much active material becomes airborne.

The active may also be only a small portion of the total powder. That raises content-uniformity questions. A development team must know that the material taken from one part of a blend represents the same dose as material taken from another.

Peptides add chemical sensitivity. Heat, interfaces and water can promote degradation or aggregation. A particle-making process that produces a beautiful aerosol may damage the molecule. A gentle process that protects the sequence may produce powder that will not disperse.

The useful product sits where those requirements overlap. Reaching that point can take repeated formulation and analytical cycles, which is why early access to a consistent peptide lot is valuable. If API quality changes while a team is tuning the powder, it becomes difficult to know whether a performance change came from the formulation or from the active itself.

Our GLP-1 peptide manufacturing guide explains the upstream synthesis, purification and scale questions. The same discipline must continue when the peptide enters the delivery system.

What should research and development buyers verify?

Start with the exact molecule. Confirm the sequence, expected molecular mass, chemical form and any modification. “GLP-1” describes a biological family, not a purchase-ready specification. ROSE-010, semaglutide and native GLP-1 are not interchangeable.

Next, separate API quality from inhalation performance. For the peptide, review identity data, chromatographic purity, content or assay basis, relevant impurities, water and stability. Make sure the reports match the batch number on the material. Our peptide quality testing guide explains what HPLC and mass spectrometry can establish and where additional methods are needed.

For a formulated powder, ask how particle size is defined and measured, how dose uniformity is assessed, what device is used and what humidity conditions the package is designed to control. If the supplier presents an aerosol result, ask whether it came from the same formulation, device and lot being discussed.

Finally, confirm the intended-use boundary. Certiva supplies peptide materials for research and development. A research peptide is not an inhaled medicine, and it should not be placed in a consumer device or used in people. A regulated finished inhaler requires a product-specific development, manufacturing and approval path.

What does ROSE-010 mean for GLP-1 suppliers and OEM teams?

The 2026 announcement is a signal that format innovation is moving alongside molecule innovation. Buyers are no longer asking only for a peptide with a given purity. Some are asking how that peptide behaves in a tablet, a depot, a nasal system or a pulmonary powder.

That creates opportunity for suppliers who can communicate clearly across the handoffs. An API manufacturer does not need to pretend it is a device company. It does need to understand which attributes matter downstream and provide material that lets formulation partners work without unnecessary uncertainty.

For GLP-1 projects, that can mean early agreement on counterion, residual solvents, water, particle handling, packaging and stability protocol. It can mean supplying a representative pilot lot before a team commits to a costly device study. It can also mean retaining samples and change-control records so unexpected results can be investigated later.

This is the practical B2B lesson from ROSE-010. The value is not in adding the word “inhaled” to an ordinary peptide listing. The value is in building a traceable material and development package around the final route.

Certiva’s quality and COA process shows how we organize batch documentation for research materials. Teams planning a GLP-1 feasibility or analytical project can also review our semaglutide research material as an example of a defined product page. It is not ROSE-010 and is not offered as an inhaled product.

The bottom line

ROSE-010 is worth watching because it does not simply chase a longer half-life. It asks whether a rapid peptide delivered through the lung can create a useful, meal-linked GLP-1 option.

The September 2026 MannKind partnership gives that idea a credible formulation and manufacturing route. The prior human research gives the molecule a reason to advance. The missing piece is direct clinical evidence for the inhaled product.

If the program succeeds, it could widen the meaning of convenience in the GLP-1 market. If it struggles, the development data will still clarify the limits of pulmonary peptide delivery. Either outcome will matter to formulation scientists, device teams and peptide suppliers.

For research buyers, the immediate lesson is simple: do not source an “inhaled GLP-1” as if it were only a vial of peptide. Define the molecule, powder, device, tests and use case separately. If your team needs a documented peptide API for an early research program, contact Certiva with the molecule, quantity and testing scope. We will confirm what fits our capabilities and what requires a specialized inhalation-development partner.

Sources

• MannKind and Rose Pharma licensing and collaboration announcement, September 9, 2026
• Rose Pharma: ROSE-010 science and development overview
• ROSE-010 Phase 2a appetite study poster
• Pulmonary delivery of a GLP-1 receptor agonist in a preclinical model

This article is educational and is not medical advice. ROSE-010 is investigational. Certiva materials are supplied for qualified research and development use, not for human consumption or self-administration.

Frequently asked questions

What is ROSE-010?

ROSE-010 is an investigational GLP-1 receptor agonist designed to act quickly and for a relatively short time. Rose Pharma is developing an inhaled dry-powder version with MannKind's Technosphere platform.

Is ROSE-010 an inhaled GLP-1?

The current program is developing ROSE-010 as an inhaled dry-powder GLP-1 product. Earlier human studies used other administration routes, so those results do not prove how the inhaled version will perform.

Is ROSE-010 the same as semaglutide or Ozempic?

No. ROSE-010 is a different, rapid-acting GLP-1 analogue with a different delivery strategy. Semaglutide is a long-acting peptide used in approved products; ROSE-010 remains investigational.

Does inhaled ROSE-010 cause weight loss?

That has not been established. A prior subcutaneous ROSE-010 study reported lower food intake at a test meal, but an inhaled formulation has not yet shown weight-loss results in a completed human efficacy trial.

Is ROSE-010 approved?

No. ROSE-010 is an investigational program. The 2026 collaboration supports development and manufacturing work toward an inhaled clinical candidate, not commercial approval.

What should buyers verify when sourcing material for inhaled peptide research?

Verify the exact peptide and chemical form, identity, purity, content and stability. For a dry-powder product, also define particle size, emitted dose, aerosol performance, moisture control, device compatibility and finished-product testing.

For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.

← More gLP-1 & weight management guides · Have a question? Start an inquiry →